The Battle of the MYMP

By Kathryn Webb

Mar 16, 2022

It’s the battle of the MYMP! Drs. Caza, Cassol, and Larsen have recently published papers discussing CXCR5 + CD8 + T cellular therapy, cubilin & amnionless protein, EXT1 & NCAM1-associated membranous lupus nephritis, & lupus nephritis. Read each paper below!

Antibody-suppressor CXCR5 ⁺ CD8 ⁺ T cellular therapy ameliorates antibody-mediated rejection following kidney transplant in CCR5 KO mice

Cubilin and amnionless protein are novel target antigens in anti–brush border antibody disease

EXT1 and NCAM1-associated membranous lupus nephritis in a cohort of patients undergoing repeat kidney biopsies

Cell type-specific mechanistic target of rapamycin-dependent distortion of autophagy pathways in lupus nephritis

Quick note: This post is to be used for informational purposes only and does not constitute medical or health advice. Each person should consult their own doctor with respect to matters referenced. Arkana Laboratories assumes no liability for actions taken in reliance upon the information contained herein.